ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
about
Mechanism of activation and inhibition of the HER4/ErbB4 kinaseEpidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interfaceThe extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationHost cell manipulation by the human pathogen Toxoplasma gondiiStructure-function relationships of ErbB RTKs in the plasma membrane of living cellsTargeting of erbB3 receptor to overcome resistance in cancer treatmentERBB3-mediated regulation of Bergmann glia proliferation in cerebellar lamination.Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptorDynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cellsTargeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.HER3 and downstream pathways are involved in colonization of brain metastases from breast cancerThe role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Kinase-mediated quasi-dimers of EGFRReceptor tyrosine kinases with intracellular pseudokinase domainsThe oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisTherapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancerErbB3 expression promotes tumorigenesis in pancreatic adenocarcinomaA system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions.Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological responseLoss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Molecular architecture of the ErbB2 extracellular domain homodimer.Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.A structural perspective on the regulation of the epidermal growth factor receptor.HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutationsIntegrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Epidermal growth factors in the kidney and relationship to hypertension.Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.The ERBB3 receptor in cancer and cancer gene therapyLigand-induced ErbB receptor dimerization.Interaction of antibodies with ErbB receptor extracellular regions.HER-2-directed, small-molecule antagonists
P2860
Q24310089-92994365-777C-4C20-A103-8AD6B15009D0Q24529941-77227F29-198E-49F8-982E-53C9B479D083Q24536067-FF20A90C-6E43-4DE0-907A-81DADF0DE28AQ24621754-B07208D5-ACD8-4E80-BE1F-621011B21959Q24650648-091A3A61-31FD-4817-9B4C-6AAAA1884B01Q26853162-B38115BC-9EDC-4FAE-8A01-16BDCCA3573EQ26864668-E5342A5C-5152-4C0E-8AEF-DEC2BE54D7F0Q27345740-3DF3870E-EB23-4AEC-9EDC-484A1D5990E6Q27646596-65F6875F-2EA1-49B8-9CAB-3FE3B1A4135AQ27657234-1FDBF33F-6A2A-4479-879F-7C35157A0803Q30524738-C3A79C75-D7D2-4B3D-8940-5C1C42D869E8Q34036131-03B34029-0B60-434E-A44C-F32CFBC97625Q34173413-8C64965A-D392-4715-BD1A-638C18C67650Q34349389-9DA7FFD0-2564-4D2D-97F5-13B50712CB57Q34352792-5348C387-69C3-486E-938D-D81265EDC9CDQ34358042-ADE39271-3719-4201-823A-A0BBEFD24054Q34493341-9A21639B-9D7C-4DA7-9B19-3C971D12CBBAQ34570753-5DFDEF69-DBD4-4978-B550-718AE9D093ABQ34582105-233D483D-E7B8-4CD0-83D2-865F36BFBCD2Q34587922-BE15DAC9-606C-446F-B628-6F52B2613A15Q34600838-105B7816-FB4B-4623-9269-6B83FDBDA145Q34619329-6EA6D39F-CFB0-407E-95FC-85E84EBAC743Q34735615-8608FFB2-7003-4ACD-8080-5388E0B85E6DQ35145024-2F37A2F3-0CA5-4074-8A9C-02CA08022A0CQ35176414-25D50560-8A29-4932-B4AE-A9FFC7611786Q35208054-D08B26D1-C362-497A-85D2-2E1E53D1838EQ35674768-11ED9FC6-B4DE-49C1-913F-2632C429EEF0Q35749374-D328B70E-5E96-4284-9217-3BD5F08E238AQ35820920-FC926E51-D922-42B8-B41C-7FAEBF7FCB70Q35966355-BD086D04-2BB7-404C-8AEE-29F468E7CC72Q36021891-81865632-AE0A-46C5-B7BB-2A379EA93E29Q36254464-461B31B4-BB4C-4F0C-8347-0077912FDEEFQ36729440-B48D4DF7-4A4B-4A60-BB4B-404C1841D058Q36772036-832537BB-8F9F-484B-9C16-CC9182414A54Q37051477-938962AB-5624-4272-B4E1-02045E9B2F41Q37090804-9066933B-CE74-4676-8713-B675C2561DE7Q37135372-9E250314-9712-4CC3-A63C-0D631FB16935Q37154122-A554A918-FD65-4BDE-9F33-2D3CF85F3E22Q37320814-3B1FE754-2E7C-41E9-90C9-FA8F4D8C2D9DQ37336019-71DA76E7-EE59-4747-AF70-60657EAF0768
P2860
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
@en
type
label
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
@en
prefLabel
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
@en
P1433
P1476
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
@en
P2093
Jeannine M Mendrola
P304
P356
10.1016/J.FEBSLET.2004.06.014
P407
P577
2004-07-01T00:00:00Z